Patents by Inventor Nicholas M. Dean

Nicholas M. Dean has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200190521
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Applicant: Excaliard Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Publication number: 20190323013
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: November 29, 2018
    Publication date: October 24, 2019
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Publication number: 20170335329
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: May 23, 2017
    Publication date: November 23, 2017
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Patent number: 9688987
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 29, 2015
    Date of Patent: June 27, 2017
    Assignees: Excaliard Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Publication number: 20170022501
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: September 25, 2015
    Publication date: January 26, 2017
    Applicant: EXCALIARD PHARMACEUTICALS, INC.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Publication number: 20150376623
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 31, 2015
    Applicants: EXCALIARD PHARMACEUTICALS, INC., ISIS PHARMACEUTICALS, INC.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Freier
  • Patent number: 9173894
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 3, 2015
    Assignee: Excaliard Pharamaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Patent number: 9157081
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: October 13, 2015
    Assignees: Isis Pharmaceuticals, Inc., Sarepta Therapeutics
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard M. Kole, Casey C. Kopczynski
  • Patent number: 9096851
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: August 4, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Patent number: 8946172
    Abstract: This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.
    Type: Grant
    Filed: August 26, 2009
    Date of Patent: February 3, 2015
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Northwestern University
    Inventors: Thomas A. Mustoe, Nicholas M. Dean, Mark Sisco, Zol Kryger, C. Frank Bennett
  • Patent number: 8772260
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: August 13, 2012
    Date of Patent: July 8, 2014
    Assignees: Isis Pharmaceuticals, Inc, Excaliard Pharmaceuticals, Inc
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Patent number: 8765703
    Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of MyD88. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding MyD88. Methods of using these compounds for modulation of MyD88 expression and for treatment of diseases associated with expression of MyD88 are provided.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: July 1, 2014
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Timothy Vickers, Nicholas M. Dean
  • Publication number: 20140005374
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Application
    Filed: July 3, 2013
    Publication date: January 2, 2014
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard M. Kole, Casey C. Kopczynski
  • Patent number: 8501703
    Abstract: Disclosed herein are compounds, compositions and methods for modulating splicing of a selected target mRNA. Further provided are uses of the disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Methods of enhancing cellular uptake, modulating tissue distribution and enhancing pharmacological activity of RNase H-independent antisense oligonucleotides are also provided.
    Type: Grant
    Filed: August 29, 2006
    Date of Patent: August 6, 2013
    Assignees: Isis Pharmaceuticals, Inc., Sarepta Therapeutics
    Inventors: C. Frank Bennett, Nicholas M. Dean, Ryszard Kole, Casey C. Kopczynski
  • Publication number: 20130190380
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: June 25, 2012
    Publication date: July 25, 2013
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Publication number: 20130190382
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Application
    Filed: August 13, 2012
    Publication date: July 25, 2013
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Publication number: 20130096176
    Abstract: The present invention provides compositions and methods for modulating the expression of growth factor gene. In particular, this invention relates to compounds, particularly oligonucleotide compounds, which, in preferred embodiments, hybridize with nucleic acid molecules encoding the Insulin Like Growth Factor I receptor (IGF-I receptor or IGF-IR) and in particular human IGF-IR. Such compounds are exemplified herein to modulate proliferation which is relevant to the treatment of proliferative and inflammatory skin disorders and cancer. It will be understood, however, that the compounds can be used for any other condition in which the IGF-IR is involved including inflammatory condition.
    Type: Application
    Filed: June 11, 2012
    Publication date: April 18, 2013
    Applicant: Antisense Therapeutics Limited
    Inventors: Christopher John WRAIGHT, George Arthur Werther, Nicholas M. Dean, Kenneth W. Dobie
  • Publication number: 20120238937
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: February 2, 2012
    Publication date: September 20, 2012
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Patent number: 8252762
    Abstract: This invention provides compounds which comprise modified oligonucleotides capable of inhibitory expression of connective tissue factor and composition containing same as well as methods of treating hyperprolific disorders and fibrotic diseases, and of reducing scarring resulting from wound healing using such compounds.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: August 28, 2012
    Assignees: Excaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, J. Gordon Foulkes, Niall O'Donnell, C. Frank Bennett, Susan M. Frier
  • Patent number: 8198253
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of HBXIP in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders.
    Type: Grant
    Filed: July 18, 2007
    Date of Patent: June 12, 2012
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Kenneth W. Dobie, Nicholas M. Dean, C. Frank Bennett